The ARF1-knockdown CRC cells formed smaller tumors than control cells, with decreases of 35.7% and 75.6% for HT29-derived tumors and 31.8% and 85.3% for DLD1-derived tumors (Figure 3F). This evidence concerns the gene ARF1 and colorectal carcinoma.